Encore Presentations
Tuesday, November 14, 2023
08:30 AM–10:00 AM
Abstract
Biosimilar Uptake and Cost Savings Analysis Before and
After Implementation of a Pharmacist-driven Substitution Program within a
National Community Oncology Network: One Year Follow-Up.
Background:
As of December 2022, 22 of the 40 biosimilar approvals in
the United States, are for the treatment of cancer or for the supportive care
of patients with cancer. Our organization is a network of community oncology
practices, representing 107 oncologists at 76 locations across 17 states.
Because our network faces formulary selection and reimbursement challenges
related to a diverse payor mix across multiple states, we sought to see the
impact of utilizing regional clinical pharmacists (RCPs) to assist with
selection of the most cost-effective biosimilar products.
Methods:
In October 2021, our network initiated an RCP-driven
biosimilar substitution program, whereby the RCP acts as a liaison between
providers and financial teams to evaluate existing drug orders and their financial
impact. We previously presented data on the financial impact to payors and
providers before and after implementation of the program from 4/1/2021 to 4/1/2022.
This study evaluates the one-year results following program implementation.
Outcomes related to biosimilar utilization as well as financial impacts to
payors, patients, and providers were assessed. Payor savings is defined as the
difference of the calculated 80% Medicare ASP+6 for the administered biosimilar
compared to the originator; patient savings is defined as the difference of the
calculated 20% Medicare ASP+6 co-insurance for the administered biosimilar
compared to the originator; provider savings is defined as the difference
between the invoiced cost of the biosimilar compared to the originator.
Results:
By the end of 2022, preferred product utilization was
achieved for > 90% of bevacizumab, trastuzumab, and rituximab orders. Use of
the preferred pegfilgrastim product increased from <20% in 4/2021 to >60%
by 12/2022. Use of filgrastim biosimilar product increased from <75% in
4/2021 to >90% by 4/2022; then decreased to 55% by 12/2022 due to trending
ASP. Payor preference prevented biosimilar switching in approximately 34% of
cases.
Conclusions:
Use of institution-preferred biosimilar products increased
across all agents in this study after implementation of the RCP-driven
biosimilar substitution program except for filgrastim. Significant cost savings
were noted for providers, payors, and patients. Barriers to switching to
institution-preferred products included non-medical switching requirements by
payors, patient assistance and compassionate use programs, and patient and/or
provider preferences.
Timeframe
|
Payor Savings
|
Patient Savings
|
Provider Savings
|
Total Savings
|
4/1/2021-9/30/2021
|
$8.0 million
|
$2.0 million
|
$11.3 million
|
$21.3 million
|
10/1/2021-4/1/2022
|
$10.8 million
|
$2.7 million
|
$10.6 million
|
$24.1 million
|
1/1/2022-12/31/2022
|
$26.4 million
|
$6.6 million
|
$23.5 million
|
$56.5 million
|
Presenting Author
Brooke Peters PharmD, BCOPAmerican Oncology Network
Authors
Kyle Brown NA
American Oncology Network
Robert Carr PharmD, BCOP, BCPS
American Oncology Network
Ashley Kohler-Gerber CPhT, CSPT
American Oncology Network
Jenny Li PharmD, BCOP, BCPS
American Oncology Network
Ta'Qyra Freeman CPhT, CSPT
American Oncology Network
Melody Chang RPh, BCOP
American Oncology Network
Darell Connor MHA, FWSPA
American Oncology Network
Bradley Winegar PharmD
American Oncology Network
Camilo Rodriguez CPhT-Adv, CSPT, PRS
American Oncology Network